Stocks NNUP Financial statements
Financial statementsNOCOPI TECHNOLOGIES INC/MD/ financial statements
Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data NOCOPI TECHNOLOGIES INC/MD/ files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
| FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.38 | 1.57 | 3.34 | 2.54 | 2.66 | 1.95 | 4.63 | 2.08 | 2.12 | 1.49 |
| Cost of revenue | 0.44 | 0.44 | 0.56 | 0.84 | 1.12 | 0.74 | 0.73 | 0.98 | 1.02 | 0.68 |
| Gross profit | 0.94 | 1.12 | 2.78 | 1.7 | 1.54 | 1.21 | 3.9 | 1.1 | 1.1 | 0.81 |
| Research and development | 0.14 | 0.15 | 0.15 | 0.17 | 0.17 | 0.18 | 0.14 | 0.16 | 0.18 | 0.18 |
| Selling and marketing | 0.24 | 0.25 | 0.39 | 0.33 | 0.36 | 0.29 | 0.49 | 0.27 | 0.32 | 0.28 |
| General and administrative | 0.29 | 0.32 | 0.37 | 0.39 | 0.53 | 0.72 | 1.22 | 2.54 | 3.9 | 0.95 |
| Operating expenses | 0.67 | 0.72 | 0.91 | 0.89 | 1.06 | 1.19 | 1.85 | 2.97 | 4.4 | 1.41 |
| Operating income | 0.27 | 0.41 | 1.87 | 0.81 | 0.48 | 0.03 | 2.05 | -1.87 | -3.3 | -0.6 |
| Interest expense | 0.01 | 0.03 | 0.01 | 0.01 | 0.01 | 0 | 0 | 0.01 | 0.02 | 0.02 |
| Interest income | 0 | 0 | 0.01 | 0.02 | 0.02 | 0.33 | 0.02 | 0.02 | ||
| Other non-operating income | -0.01 | -0.03 | -0.01 | 0 | 0.01 | 0.02 | 0.06 | 0.31 | 0.62 | 0.45 |
| Pre-tax income | 0.38 | 1.86 | 0.81 | 0.49 | 0.04 | 2.11 | -1.56 | -2.68 | -0.15 | |
| Income tax | 0.21 | 0.05 | -0.02 | -0.01 | 0.29 | -0.12 | 0 | 0 | ||
| Net income | 0.26 | 0.38 | 1.66 | 0.75 | 0.51 | 0.05 | 1.81 | -1.44 | -2.68 | -0.15 |
| EBITDA | 0.28 | 0.41 | 1.88 | 0.82 | 0.5 | 0.06 | 2.08 | -1.82 | -3.27 | -0.59 |
| EPS, basic | 0.00 | 0.01 | 0.03 | 0.01 | 0.01 | 0.01 | 0.24 | -0.15 | -0.25 | -0.01 |
| EPS, diluted | 0.00 | 0.01 | 0.03 | 0.01 | 0.01 | 0.01 | 0.24 | -0.15 | -0.25 | -0.01 |
| Shares, basic (weighted) | 58.6 | 58.6 | 58.6 | 59.4 | 64.1 | 6.74 | 7.58 | 9.67 | 10.5 | 10.8 |
| Shares, diluted (weighted) | 58.6 | 58.9 | 59 | 59.8 | 64.2 | 6.74 | 7.58 | 9.67 | 10.5 | 10.8 |
Balance sheet
| FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 0.2 | 0.36 | 0.4 | 0.69 | 1.36 | 1.85 | 0.92 | 2.27 | 10.8 | 11.6 |
| Short-term investments | 4.39 | 7.99 | ||||||||
| Receivables | 0.24 | 0.29 | 0.58 | 1.35 | 1.28 | 0.97 | 1.1 | 1.12 | 1.23 | 0.94 |
| Inventory | 0.07 | 0.11 | 0.13 | 0.13 | 0.32 | 0.42 | 0.49 | 0.45 | 0.35 | 0.46 |
| Other current assets | 0.03 | 0.04 | 0.04 | 0.14 | 0.1 | 0.16 | 0.1 | 0.12 | 0.16 | 0.14 |
| Total current assets | 0.54 | 0.8 | 1.16 | 2.3 | 3.07 | 3.4 | 7.03 | 12.1 | 12.6 | 13.1 |
| Property, plant and equipment | 0.02 | 0.01 | 0.01 | 0.07 | 0.09 | 0.09 | 0.06 | 0.04 | 0.02 | 0.01 |
| Lease right-of-use assets | 0.2 | 0.16 | 0.12 | 0.07 | 0.02 | 0.03 | 0.16 | |||
| Goodwill | 0 | |||||||||
| Intangible assets | 0 | |||||||||
| Other non-current assets | 1.35 | 1.16 | 0.72 | 0.3 | ||||||
| Total assets | 0.56 | 0.81 | 2.52 | 3.53 | 3.87 | 3.79 | 9.62 | 14 | 13.9 | 14 |
| Accounts payable | 0.03 | 0 | 0.02 | 0.04 | 0.01 | 0 | 0.1 | 0.03 | 0.02 | 0.03 |
| Accrued liabilities | 0.46 | 0.36 | 0.16 | 0.23 | 0.18 | 0.15 | 0.17 | 0.09 | 0.11 | 0.15 |
| Deferred revenue | 0.11 | 0.1 | ||||||||
| Total current liabilities | 0.74 | 0.6 | 0.35 | 0.47 | 0.27 | 0.2 | 0.61 | 1.49 | 0.19 | 0.29 |
| Lease liabilities | 0.16 | 0.12 | 0.07 | 0.02 | 0 | 0 | 0.09 | |||
| Other non-current liabilities | 0.09 | 0.07 | 0.04 | 0.01 | 0.17 | 0.13 | 0.09 | 0.14 | ||
| Total liabilities | 0.74 | 0.6 | 0.55 | 0.74 | 0.42 | 0.28 | 0.8 | 1.62 | 0.28 | 0.43 |
| Paid-in capital | 12.4 | 12.4 | 12.4 | 12.5 | 12.6 | 13.2 | 16.7 | 21.6 | 25.6 | 25.7 |
| Retained earnings | -13.2 | -12.8 | -11.1 | -10.3 | -9.8 | -9.75 | -7.93 | -9.37 | -12 | -12.2 |
| Shareholders' equity | -0.18 | 0.22 | 1.97 | 2.79 | 3.45 | 3.51 | 8.82 | 12.4 | 13.6 | 13.6 |
| Total equity | -0.18 | 0.22 | 1.97 | 2.79 | 3.45 | 3.51 | 8.82 | 12.4 | 13.6 | 13.6 |
| Total liabilities and equity | 0.56 | 0.81 | 2.52 | 3.53 | 3.87 | 3.79 | 9.62 | 14 | 13.9 | 14 |
| Shares outstanding | 58.6 | 58.6 | 58.6 | 61 | 67.4 | 6.75 | 9.25 | 10.5 | 10.8 | 10.8 |
Cash flow statement
| FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Net income | 0.26 | 0.38 | 1.66 | 0.75 | 0.51 | 0.05 | 1.81 | -1.44 | -2.68 | -0.15 |
| Depreciation and amortization | 0.01 | 0.01 | 0.01 | 0.01 | 0.02 | 0.03 | 0.03 | 0.05 | 0.03 | 0.01 |
| Stock-based compensation | 0 | 0 | 0 | 1.32 | 2.73 | 0.13 | ||||
| Deferred income tax | 0.11 | -0.06 | -0.05 | -0.39 | ||||||
| Change in receivables | 0.01 | -0.05 | -0.29 | -0.77 | 0.06 | 0.31 | -0.13 | -0.02 | -0.11 | 0.3 |
| Change in inventory | -0.03 | -0.04 | -0.02 | 0.01 | -0.2 | -0.1 | -0.06 | 0.05 | 0.14 | -0.14 |
| Change in payables | -0.03 | -0.12 | -0.19 | 0.11 | -0.05 | -0.1 | 0.23 | -0.07 | -0.01 | 0.01 |
| Cash from operations | 0.2 | 0.18 | 0.04 | 0.36 | 0.7 | 0.51 | -0.04 | -0.02 | 0.59 | 0.71 |
| Capital expenditures | -0 | -0.01 | -0 | -0.07 | -0.04 | -0.03 | -0 | -0.03 | -0.01 | 0 |
| Purchases of investments | -3.6 | |||||||||
| Cash from investing | -0 | -0.01 | -0 | -0.07 | -0.04 | -0.03 | -4.39 | -3.63 | 7.98 | 0 |
| Stock issued | 0 | 3.5 | 5 | |||||||
| Cash from financing | -0.01 | -0.01 | 0.01 | 0 | 3.5 | 5 | ||||
| Net change in cash | 0.19 | 0.16 | 0.04 | 0.29 | 0.67 | 0.48 | -0.93 | 1.35 | 8.57 | 0.71 |
| Free cash flow | 0.2 | 0.17 | 0.04 | 0.29 | 0.66 | 0.48 | -0.04 | -0.05 | 0.58 | 0.71 |
| Interest paid | 0.01 | 0.01 | 0 | |||||||
| Income taxes paid | 0.04 | 0.1 | 0.05 | 0.04 | 0 | 0.18 |
Key metrics
Profitability
| Metric | Value | How it is calculated |
|---|---|---|
| Gross margin | 44.7% | Gross profit / revenue. |
| Operating margin | -53.5% | Operating income / revenue. |
| EBITDA margin | -52.7% | EBITDA (operating income + depreciation and amortization) / revenue. |
| Pre-tax margin | -32.7% | Pre-tax income / revenue. |
| Net margin | -32.7% | Net income / revenue. |
| FCF margin | 27.0% | Free cash flow (cash from operations - capital expenditures) / revenue. |
| Operating cash flow margin | 27.7% | Cash from operations / revenue. |
| Return on equity (ROE) | -4.5% | Net income / average shareholders' equity (opening and closing). Not shown when equity is negative. |
| Return on assets (ROA) | -4.1% | Net income / average total assets. |
| Return on invested capital (ROIC) | -22.5% | Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%. |
| R&D / revenue | 9.8% | Research and development expense / revenue. |
| Stock-based pay / revenue | 9.5% | Stock-based compensation (from the cash flow statement) / revenue. |
| Capex / revenue | 0.7% | Capital expenditures / revenue. |
| D&A / revenue | 0.8% | Depreciation and amortization / revenue. |
Growth
| Metric | Value | How it is calculated |
|---|---|---|
| Revenue growth, 1y | -29.5% | Revenue vs the same period a year earlier. Only from a positive base. |
| Revenue CAGR, 3y | -31.4% | Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive. |
| Revenue CAGR, 5y | -10.9% | Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive. |
| Gross profit growth, 1y | -26.1% | Gross profit vs the same period a year earlier. Only from a positive base. |
| Gross profit CAGR, 3y | -40.7% | Compound annual growth of gross profit over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive. |
| Gross profit CAGR, 5y | -11.9% | Compound annual growth of gross profit over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive. |
| Operating cash flow growth, 1y | 20.0% | Operating cash flow vs the same period a year earlier. Only from a positive base. |
| Operating cash flow CAGR, 5y | 0.3% | Compound annual growth of operating cash flow over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive. |
| Free cash flow growth, 1y | 22.1% | Free cash flow vs the same period a year earlier. Only from a positive base. |
| Free cash flow CAGR, 5y | 1.5% | Compound annual growth of free cash flow over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive. |
| Book value growth, 1y | -0.3% | Book value vs the same period a year earlier. Only from a positive base. |
| Book value CAGR, 3y | 15.5% | Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive. |
| Book value CAGR, 5y | 31.5% | Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive. |
| Total assets growth, 1y | 0.8% | Total assets vs the same period a year earlier. Only from a positive base. |
| Total assets CAGR, 3y | 13.4% | Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive. |
| Total assets CAGR, 5y | 29.4% | Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive. |
| Share count change, 1y | 2.5% | Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution. |
| Share count change per year, 3y | 12.5% | Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution. |
| Share count change per year, 5y | -30.0% | Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution. |
Balance sheet health
| Metric | Value | How it is calculated |
|---|---|---|
| Current ratio | 12.1x | Current assets / current liabilities. |
| Quick ratio | 10.4x | (Cash + short-term investments + receivables) / current liabilities. |
| Cash ratio | 9.32x | (Cash + short-term investments) / current liabilities. |
| Liabilities / assets | 9.7% | Total liabilities / total assets. |
| Interest coverage | -44.1x | Operating income / interest expense. |
| Working capital | $12.7M | Current assets - current liabilities. |
| Goodwill and intangibles / assets | 4.9% | (Goodwill + intangible assets) / total assets. |
| Tangible book value | $13.7M | Shareholders' equity - goodwill - intangible assets. |
Efficiency
| Metric | Value | How it is calculated |
|---|---|---|
| Asset turnover | 0.13x | Revenue / average total assets. |
| Fixed asset turnover | 6.34x | Revenue / average property, plant and equipment. |
| Inventory turnover | 0.65x | Cost of revenue / average inventory. |
| Days inventory | 563 days | 365 x average inventory / cost of revenue. |
| Receivables turnover | 1.58x | Revenue / average receivables. |
| Days sales outstanding | 231 days | 365 x average receivables / revenue. |
| Days payables | 142 days | 365 x average accounts payable / cost of revenue. |
| Cash conversion cycle | 653 days | Days inventory + days sales outstanding - days payables. |
| Capex / operating cash flow | 2.4% | Capital expenditures / cash from operations, when that is positive. |
Per share
| Metric | Value | How it is calculated |
|---|---|---|
| EPS, diluted | -$0.06 | Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS. |
| Revenue per share | $0.18 | Revenue / diluted weighted shares. |
| FCF per share | $0.05 | Free cash flow / diluted weighted shares. |
| Operating cash flow per share | $0.05 | Cash from operations / diluted weighted shares. |
| Book value per share | $1.23 | Shareholders' equity / shares outstanding (diluted weighted shares when not reported). |
| Tangible book per share | $1.16 | Tangible book value / shares outstanding. |
| Cash per share | $0.91 | (Cash + short-term investments) / shares outstanding. |
Valuation
| Metric | Value | How it is calculated |
|---|---|---|
| Market cap | $19.8M | Share price x shares outstanding. |
| Enterprise value | $9.2M | Market cap + total debt - cash - short-term investments. |
| P/S | 9.90x | Market cap / revenue. |
| P/B | 1.37x | Market cap / shareholders' equity. Only when equity is positive. |
| Price / tangible book | 1.45x | Market cap / tangible book value, when positive. |
| P/FCF | 36.6x | Market cap / free cash flow. Only when free cash flow is positive. |
| P/OCF | 35.7x | Market cap / cash from operations, when positive. |
| EV/Sales | 4.57x | Enterprise value / revenue. |
| EV/FCF | 16.9x | Enterprise value / free cash flow, when both are positive. |
| FCF yield | 2.7% | Free cash flow / market cap. |
| Earnings yield | -3.3% | Net income / market cap (the inverse of P/E). |
What was NOCOPI TECHNOLOGIES INC/MD/'s revenue in fiscal 2025?
NOCOPI TECHNOLOGIES INC/MD/ reported revenue of $1.5M for fiscal 2025, 29.5% lower than the year before.
Was NOCOPI TECHNOLOGIES INC/MD/ profitable in fiscal 2025?
No. It reported a net loss of $154.9K.
How much free cash flow did NOCOPI TECHNOLOGIES INC/MD/ generate in fiscal 2025?
Cash from operations of $713.9K minus capital expenditures of $0.0 left free cash flow of $713.9K.